An artificial intelligence model appeared to predict adverse events associated with novel combination therapies for various cancer types, according to study results presented at American Association for Cancer Research Annual Meeting.
“In our lab, we aim to identify effective multitargeted therapies against cancer and translate the findings to the clinic,” Bart Westerman, PhD, associate professor in the department of neurosurgery at Brain Tumor Center Amsterdam, told Healio. “We found that many obstacles prohibit this translation, one of them being adverse events, which are